[Etiopathogenic, clinical-diagnostic and therapeutic aspects of the burning mouth syndrome. Research and treatment protocols in a patient group].
BACKGROUND
Burning mouth syndrome (BMS) is a frequently seen pathology characterised by burning tongue and oral pain without macroscopic structural lesions to the mucose. BMS etiopathology isn't known and therapy is merely empirical and unsatisfactory.


METHODS
To evaluate the hypothesis that this syndrome would originate by a small diameter peripheral neuropathy combined to a mucosal trophic lesion, 37 patients, (7 male, 30 female, between 36 and 79 years, mean 54 years) affected by BMS, consecutively observed in our dispensary were submitted to a series of examinations and to therapeutical approach used in neuropathic painful syndromes. All patients were submitted to a complete stomatological exam and X-ray pantomography to exclude mucosal macroscopical lesions and dentistry illnesses. All patients executed sierological exams (glycemia, etc.), neurological exam, tongue and foot dorsum quantitative sensory examination, tongue and face telethermography. A few patients (3 male, 10 female; age 34 to 53, mean 49) were submitted to mucosal tongue biopsy, analyzed by optic microscopy and immunofluorescency following treatment with anticytoplasmatic neuronal proteins antibodies (protein gene product 9.5).


RESULTS
These examinations showed subclinical polyneuropathy in 50% of patients. In particular, a loss of function in small diameter nervous fibres in about 50% of patients was observed. Histological examination of tongue mucose revealed a moderate atrophy in 70% patients.


CONCLUSIONS
All patients were submitted to an antalgic therapy, with non-antiflammatory drugs used in neuropathic painful syndromes (quercetine, antiepileptic drugs benzodyazepinein and gabaergic, topical application of capsaicine solutions).
Lauritano
D
D
Istituto di Discipline Odontostomatologiche, Università degli Studi, Milano.
Spadari
F
F
Formaglio
F
F
Zambellini Artini
M
M
Salvato
A
A
D000328:Adult; D000368:Aged; D000700:Analgesics / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D002054:Burning Mouth Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D002211:Capsaicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000294:innervation; D010523:Peripheral Nervous System Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D011115:Polyneuropathies / Q000150:complications / Q000175:diagnosis; D014059:Tongue / Q000294:innervation
D000700:Analgesics; D001569:Benzodiazepines; D002211:Capsaicin